Lentiviral Vector Global Market Report 2024

The lentiviral vector market size has grown rapidly in recent years. It will grow from $12.5 billion in 2023 to $14.37 billion in 2024 at a compound annual growth rate (CAGR) of 15%. The growth observed in the historic period can largely be attributed to several factors, including the prevalence of genetic disorders driving demand for gene delivery solutions, expansions within the biotech and pharmaceutical industries, increased investment in clinical trials for gene therapy, and regulatory approvals facilitating advancements in gene therapy technologies.

The lentiviral vector market size is expected to see rapid growth in the next few years. It will grow to $25.5 billion in 2028 at a compound annual growth rate (CAGR) of 15.4%. Forecasted growth is driven by personalized medicine expansion, gene editing innovations, rare disease therapy demand, lentiviral vector adoption, genomic medicine funding, and manufacturing scalability focus. Major trends include research and development expansion, integration in CAR-T cell therapy, next-generation vector development, adoption in vaccine development, and production technology advancements.

The lentiviral vectors market is poised for significant growth, driven by the increasing prevalence of chronic diseases worldwide. Chronic diseases, characterized by long-term medical conditions that progress slowly over time, are on the rise due to factors such as aging populations, unhealthy lifestyles, urbanization, and environmental influences. Lentiviral vectors have emerged as versatile and efficient tools for developing vaccines and treatment strategies to address the growing burden of chronic diseases, thereby improving patient outcomes. For example, a report published by the National Library of Medicine projected a substantial increase in the number of individuals affected by chronic illnesses, with an estimated 99.5% rise from 71.522 million in 2020 to around 142.66 million by 2050. This escalation underscores the critical role of lentiviral vectors in combating chronic diseases and meeting the escalating healthcare demands.

Key players in the lentiviral vectors market are concentrating their efforts on advancing LV vector production platforms to enhance the efficiency and robustness of lentivirus vector manufacturing for cell-based immuno-oncology therapies. One such innovative platform is LentiSure, designed to optimize the production of lentiviral vectors for cell-based immuno-oncology therapies. Launched by Yposkesi sk pharmteco in May 2023, LentiSure aims to bolster the resilience and efficiency of lentivirus production, catering to the escalating demand for scalable and reliable viral vector manufacturing technologies in cell and gene therapies. With features such as consistent product quality and high productivity, LentiSure offers promise in accelerating the development and commercialization of cell-based immuno-oncology therapies, addressing the unmet medical needs associated with chronic diseases.

In June 2021, Charles River Laboratories, a US-based pharmaceutical company, completed the acquisition of Vigene Biosciences for $292.5 million. This strategic acquisition was aimed at bolstering Charles River's gene therapy capabilities, particularly in the rapidly expanding cell and gene therapy contract development and manufacturing organization (CDMO) sectors for viral vectors and plasmid DNA. Vigene Biosciences, a US-based provider of viral vector-based gene delivery services and products, aligned with Charles River's strategic objectives, strengthening its position in the dynamic landscape of gene therapy and lentiviral vectors.

Major companies operating in the lentiviral vector market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Agilent Technologies Inc., Amgen Inc., Merck KGaA, Lonza Group Ag, Cytiva, Charles River Laboratories, Bio-Rad Laboratories Inc., Promega Corporation, Takara Bio Inc., Sino Biological Inc., OriGene Technologies Inc., Applied Biological Materials Inc., Oxford Biomedica, Sirion-Biotech GmbH, Yposkesi.

North America was the largest region in the lentiviral vector market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lentiviral vector market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lentiviral vector market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A lentiviral vector is a viral vector derived from lentiviruses, a subgroup of retroviruses known for their ability to integrate genetic material into the DNA of host cells. These vectors are widely used in molecular biology and gene therapy applications to deliver genetic material into target cells for purposes such as gene expression, gene silencing, or genetic modification.

Key products in the lentiviral vector category include kits, reagents, and consumables. Lentiviral vector kits provide a comprehensive set of tools and components necessary for generating and manipulating lentiviral vectors. These kits find application across various indications such as cancer, genetic disorders, infectious diseases, veterinary diseases, and more. Users of lentiviral vector products include biotechnology companies, pharmaceutical companies, contract research organizations (CROs), as well as academic and research institutes.

The lentiviral vector market research report is one of a series of new reports that provides lentiviral vector market statistics, including lentiviral vector industry global market size, regional shares, competitors with a lentiviral vector market share, detailed lentiviral vector market segments, market trends and opportunities, and any further data you may need to thrive in the lentiviral vector industry. This lentiviral vector market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lentiviral vector market consists of sales of 3rd generation lentiviral vectors, Lenti-ORF clones, and lentiviral particles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.